{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:23Z","timestamp":1785909143110,"version":"3.56.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Severe Fever with Thrombocytopenia Syndrome (SFTS), a highly fatal tick-borne infectious disease caused by SFTS virus (SFTSV), currently lacks globally approved specific antiviral drugs or vaccines, although favipiravir was approved in Japan for SFTS treatment in June 2024 based on data from non-randomized, uncontrolled single-arm trials. Antibody engineering has emerged as a core strategy against SFTSV, leveraging its advantages of high specificity, potent neutralizing activity, and engineerability. This review systematically examines the mechanisms of action and preclinical progress of monoclonal antibodies, nanobodies, and bispecific antibodies (bsAbs) for SFTS treatment. It analyzes translational challenges\u2014including immunogenicity, manufacturing processes, cost control, drug resistance, and clinical trial design\u2014and proposes a strategic prioritization matrix and future research directions such as multispecific antibody development, artificial intelligence (AI)-assisted design, combination therapy strategies, and international multicenter collaboration. This review aims to provide a systematic reference for the clinical translation of SFTS antibody therapeutics.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1888718","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:39:39Z","timestamp":1785908379000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody engineering for SFTS treatment: frontier progress and translational challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinhan","family":"Yu","sequence":"first","affiliation":[{"name":"School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1352014","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Andreas","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Anroop","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ddr.21461","article-title":"Dose translation between laboratory animals and human in preclinical and clinical phases of drug development","volume":"79","author":"Anroop","year":"2018","journal-title":"Drug Dev. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1298473","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Anshu","year":"2016","journal-title":"J. Immunol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1012889","DOI":"10.1371\/journal.ppat.1012889","article-title":"Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge","volume":"21","author":"Bang","year":"2025","journal-title":"PLoS Pathog."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1080\/21645515.2021.1976580","article-title":"Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection","volume":"17","author":"Bronwyn","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Chantal","year":"2024","journal-title":"BioDrugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105929","DOI":"10.1016\/j.jcv.2026.105929","article-title":"Early viral load outperforms cytokines and lymphocytes in predicting SFTS prognosis: a dynamic immune profiling study","volume":"183","author":"Chen","year":"2026","journal-title":"J. Clin. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1730089","DOI":"10.3389\/fimmu.2026.1730089","article-title":"Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome","volume":"17","author":"Chendan","year":"2026","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1624290","DOI":"10.3389\/fimmu.2025.1624290","article-title":"Latest advances and prospects in the pathogenesis, animal models, and vaccine research of severe fever with thrombocytopenia syndrome virus","volume":"16","author":"Chenghao","year":"2025","journal-title":"Front. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00533","DOI":"10.1128\/jvi.00533-25","article-title":"Molecular mechanism of potently neutralizing human monoclonal antibodies against severe fever with thrombocytopenia virus infection","volume":"99","author":"Chuansong","year":"2025","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2231","DOI":"10.1002\/rmv.2231","article-title":"Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines","volume":"31","author":"Daniele","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1038\/s41467-023-41804-7","article-title":"Cryo-EM structure of severe fever with thrombocytopenia syndrome virus","volume":"14","author":"Du","year":"2023","journal-title":"Nat. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13036-024-00418-3","article-title":"Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation","volume":"18","author":"Eun Byeol","year":"2024","journal-title":"J. Biol. Eng."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/pharmaceutics15051538","article-title":"Uses and challenges of antiviral polyclonal and monoclonal antibody therapies","volume":"15","author":"Evi","year":"2023","journal-title":"Pharmaceutics"},{"key":"B16","unstructured":"Notification of Additional Indication Approval for Antiviral Drug \u201cAvigan\n          \n          2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1073\/pnas.1603827113","article-title":"Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion","volume":"113","author":"Halldorsson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.lanwpc.2024.101133","article-title":"Global epidemiology of severe fever with thrombocytopenia syndrome virus in human and animals: a systematic review and meta-analysis","volume":"48","author":"Haoliang","year":"2024","journal-title":"Lancet Reg. Health West Pac."},{"key":"B19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: from discovery to AI-driven design","volume":"14","author":"Haoran","year":"2025","journal-title":"Biology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Huanbo","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"B21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.imj.2021.10.001","article-title":"Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome","volume":"1","author":"Jia-Chen","year":"2022","journal-title":"Infect. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/vaccines13030262","article-title":"A hidden guardian: the stability and spectrum of antibody-dependent cell-mediated cytotoxicity in COVID-19 response in chinese adults","volume":"13","author":"Jinge","year":"2025","journal-title":"Vaccines"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3201\/eid3102.240251","article-title":"Adaptive design for phase II\/III platform trial of lassa fever therapeutics","volume":"31","author":"Josephine","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e91679","DOI":"10.1371\/journal.pone.0091679","article-title":"Concurrent measurement of dynamic changes in viral load, serum enzymes, T cell subsets, and cytokines in patients with severe fever with thrombocytopenia syndrome","volume":"9","author":"Jun","year":"2014","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00705-024-05968-x","article-title":"Characterization of antibodies targeting severe fever with thrombocytopenia syndrome virus glycoprotein Gc","volume":"169","author":"Kaori","year":"2024","journal-title":"Arch. Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41590-022-01225-y","article-title":"Catching the breadth of broadly protective antibodies to SARS-CoV-2","volume":"23","author":"Kevin","year":"2022","journal-title":"Nat. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1007375","DOI":"10.1371\/journal.ppat.1007375","article-title":"An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus","volume":"15","author":"Ki Hyun","year":"2019","journal-title":"PLoS Pathog."},{"key":"B28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through fc engineering","volume":"35","author":"Ko","year":"2021","journal-title":"BioDrugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41423-021-00752-2","article-title":"Neutralizing antibodies for the prevention and treatment of COVID-19","volume":"18","author":"Lanying","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/zph.12634","article-title":"Socioeconomic burden of severe fever with thrombocytopenia syndrome in endemic areas of Anhui Province, eastern China","volume":"66","author":"Lei","year":"2019","journal-title":"Zoonoses Public Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1038\/s41467-026-71008-8","article-title":"Molecular evolution and spatial transmission of severe fever with thrombocytopenia syndrome virus","volume":"17","author":"Leng","year":"2026","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e38291","DOI":"10.1371\/journal.pone.0038291","article-title":"Critical epitopes in the nucleocapsid protein of SFTS virus recognized by a panel of SFTS patients derived human monoclonal antibodies","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liming","year":"2017","journal-title":"Protein Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e170236","DOI":"10.1172\/JCI170236","article-title":"Preparing for the next viral threat with broad-spectrum antivirals","volume":"133","author":"Marwah","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"465722","DOI":"10.1016\/j.chroma.2025.465722","article-title":"Trends and challenges in bispecific antibody production","volume":"1744","author":"Mikhail","year":"2025","journal-title":"J. Chromatogr. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"808098","DOI":"10.3389\/fcimb.2022.808098","article-title":"The endless wars: severe fever with thrombocytopenia syndrome virus, host immune and genetic factors","volume":"12","author":"Min","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1016\/j.apsb.2024.03.016","article-title":"Single-domain antibodies as therapeutics for solid tumor treatment","volume":"14","author":"Mingkai","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41541-020-00257-5","article-title":"Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development","volume":"5","author":"Nathen","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/2211-5463.13850","article-title":"Nanobody engineering: computational modelling and design for biomedical and therapeutic applications","volume":"15","author":"Nehad","year":"2024","journal-title":"FEBS Open Bio"},{"key":"B40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s42003-021-01790-2","article-title":"Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity","volume":"4","author":"Ole","year":"2021","journal-title":"Commun. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/bioengineering1040188","article-title":"Trends in upstream and downstream process development for antibody manufacturing","volume":"1","author":"Petra","year":"2014","journal-title":"Bioengineering"},{"key":"B42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/bs.apcsb.2024.10.010","article-title":"Exploring immunotherapy to control human infectious diseases","volume":"144","author":"Praveen","year":"2025","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"116593","DOI":"10.1016\/j.celrep.2025.116593","article-title":"Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV","volume":"44","author":"Qerqez","year":"2025","journal-title":"Cell Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal antibody engineering and design to modulate fcrn activities: a comprehensive review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1406040","DOI":"10.3389\/fimmu.2024.1406040","article-title":"Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays","volume":"15","author":"Robin","year":"2024","journal-title":"Front. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Sabue","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Shannon","year":"2007","journal-title":"FASEB J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0009103","DOI":"10.1371\/journal.pntd.0009103","article-title":"A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Suemori","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/v14061184","article-title":"Infection route impacts the pathogenesis of severe fever with thrombocytopenia syndrome virus in ferrets","volume":"14","author":"Su-Jin","year":"2022","journal-title":"Viruses"},{"key":"B50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/antib8020036","article-title":"Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation","volume":"8","author":"Vicki","year":"2019","journal-title":"Antibodies"},{"key":"B51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00438-025-02319-6","article-title":"Weakened invasion of severe fever with thrombocytopenia syndrome bunyavirus beneficial to its immune escape by multi-site mutation of glycoprotein","volume":"300","author":"Wang","year":"2025","journal-title":"Mol. Genet. Genomics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"117248","DOI":"10.1016\/j.celrep.2026.117248","article-title":"Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groups","volume":"45","author":"Wang","year":"2026","journal-title":"Cell Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"William","year":"2017","journal-title":"Protein Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1291836","DOI":"10.3389\/fimmu.2023.1291836","article-title":"Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment","volume":"14","author":"Xiaohan","year":"2023","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0012216","DOI":"10.1371\/journal.pntd.0012216","article-title":"Identification and characterization of three monoclonal antibodies targeting the SFTSV glycoprotein and displaying a broad spectrum recognition of SFTSV-related viruses","volume":"18","author":"Xiaoli","year":"2024","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"eady9025","DOI":"10.1126\/scitranslmed.ady9025","article-title":"A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical models","volume":"17","author":"Xilin","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e136855","DOI":"10.1172\/jci.insight.136855","article-title":"A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo","volume":"5","author":"Xilin","year":"2020","journal-title":"JCI Insight"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1128\/CVI.00222-13","article-title":"Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic fever virus","volume":"20","author":"Xiling","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"110799","DOI":"10.1016\/j.virol.2026.110799","article-title":"Favipiravir's clinical potential for treating severe fever with thrombocytopenia syndrome (SFTS): a narrative review","volume":"617","author":"Xinhan","year":"2026","journal-title":"Virology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1038\/s41467-024-51108-z","article-title":"A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection","volume":"15","author":"Xuanxiu","year":"2024","journal-title":"Nat. Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/19420862.2018.1553476","article-title":"Structure, heterogeneity and developability assessment of therapeutic antibodies","volume":"11","author":"Yingda","year":"2018","journal-title":"MAbs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/infdis\/jis452","article-title":"Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome","volume":"206","author":"Yulan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e2400163121","DOI":"10.1073\/pnas.2400163121","article-title":"Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model","volume":"121","author":"Zhen","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jcv.2016.03.017","article-title":"The prospective evaluation of viral loads in patients with severe fever with thrombocytopenia syndrome","volume":"78","author":"Zhen-Dong","year":"2016","journal-title":"J. Clin. Virol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1151888","DOI":"10.3389\/fimmu.2023.1151888","article-title":"Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development","volume":"14","author":"Zuben","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1888718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:39:40Z","timestamp":1785908380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1888718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":65,"alternative-id":["10.3389\/fmicb.2026.1888718"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1888718","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1888718"}}